Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085108" target="_blank" >RIV/00216224:14110/15:00085108 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/15:43910363 RIV/61989592:15110/15:33155482 RIV/00179906:_____/15:10312768 RIV/00064173:_____/15:#0000500 and 2 more

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma

Original language description

Aim: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. Patients and Methods: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. Results: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p&lt;0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

35

Issue of the periodical within the volume

11

Country of publishing house

GR - GREECE

Number of pages

8

Pages from-to

6303-6310

UT code for WoS article

000363794900075

EID of the result in the Scopus database

—